Qch Maximum Strength Mucus Relief 617 Liquid
NDC Package 83324-144-06
Package Information
Qch Maximum Strength Mucus Relief 617 (dextromethorphan hbr, guaifenesin, phenylephrine hcl) liquids is • do not take more than 6 doses in any 24-hour period • measure only with dosing cup provided • do not use dosing cup with other products • dose as follows or as directed by a doctor • Adults and children 12 years and older: 20 ml in dosing cup provided every 4 hours. This formulation utilizes a liquid delivery system. Marketed by Chain Drug Marketing Association Inc., this product is identified by NDC 83324-144 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 1043543 - dextromethorphan HBr 5 MG / guaiFENesin 100 MG / phenylephrine HCl 2.5 MG in 5 mL Oral Solution
- RxCUI: 1043543 - dextromethorphan hydrobromide 1 MG/ML / guaifenesin 20 MG/ML / phenylephrine hydrochloride 0.5 MG/ML Oral Solution
- RxCUI: 1043543 - dextromethorphan HBr 20 MG / guaifenesin 400 MG / phenylephrine HCl 10 MG per 20 ML Oral Solution
- RxCUI: 1043543 - dextromethorphan HBr 5 MG / guaifenesin 100 MG / phenylephrine HCl 2.5 MG per 5 ML Oral Solution
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 83324 - Chain Drug Marketing Association Inc.
- 83324-144 - Qch Maximum Strength Mucus Relief 617
- 83324-144-06 - 177 mL in 1 BOTTLE
- 83324-144 - Qch Maximum Strength Mucus Relief 617
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83324-144-06 identifies a specific commercial package of 177 ml in 1 bottle of Qch Maximum Strength Mucus Relief 617, a human over the counter drug labeled by Chain Drug Marketing Association Inc.. This liquid is formulated for oral use and contains dextromethorphan hydrobromide; guaifenesin; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chain Drug Marketing Association Inc. on September 06, 2024. The current certification is valid through December 31, 2026.
How is this Chain Drug Marketing Association Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83324014406. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
